AIDOT (CEO Jung Jae-hoon) announced that a China patent application related to Cerviray AI has been successfully registered under the title “Deep Learning System.”
The “Deep Learning System” patent covers the general configuration and operation of the Cerviray AI system. With patent registration now completed in China—following Korea—AIDOT stated that it can better protect the underlying technologies used in its AI solutions that are currently being developed and provided as services.
More specifically, the patent defines an AI analysis system composed of key modules—a learning module, tuning module, transmission module, storage module, and diagnosis module—as an independent claim describing the software process. The patent also features capabilities such as displaying real-time analysis information and updating training data.
Because of this structure, the company said the patent is significant in that it broadly protects distinctive features of AI-based lesion analysis and diagnostic support software used in cervical cancer screening.
CEO Jung Jae-hoon commented that while the company has faced challenges in advancing its China business in recent years, this patent registration provides a stronger basis for protecting AIDOT’s intellectual property and may reduce the risks associated with entering the Chinese market. He added that inquiries from Chinese partners about adopting Cerviray have recently increased, prompting the company to re-examine expansion into China.
AIDOT also said it has been invited to a gynecology/obstetrics academic conference in Shanghai (July 15–16) and is resuming promotional activities for the Cerviray system as it continues to pursue opportunities in China. The company stated that it plans to finalize China-related regulatory approval issues that have been underway and restart full-scale commercialization in China within the year.
Meanwhile, AIDOT noted that it has been recognized for its technology through selection for various government programs since its founding, and that it is building a portfolio that includes Cerviray AI, real-time GI endoscopy AI solutions GIGA dot AI and COLON dot AI, and the microbiome-based alcoholic liver disease diagnostic system BIO dot AI. In addition to Cerviray AI, which the company says is already being commercialized successfully, AIDOT stated that it has completed development of subsequent products and is accelerating preparations for commercialization.
July 14, 2023 / Korea Economic TV / Reporter Park Jun-sik
